Synonyms:
Status: Phase 2
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: BPD4DGQ314

Pharmacology

Action Mechanism of Action Reference
BINDING AGENT B-lymphocyte antigen CD20 binding agent PubMed PubMed
Primary Target
CD20 (membrane-spanning 4-domains, subfamily A, member 1)

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Arthritis, Rheumatoid 2 D001172 ClinicalTrials
Purpura, Thrombocytopenic, Idiopathic 1 D016553 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 D054198 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 1 D016403 ClinicalTrials
Lymphoma 1 D008223 ClinicalTrials
Lymphoma, Non-Hodgkin 1 D008228 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 1 D015451 ClinicalTrials
Lymphoma, Follicular 1 D008224 ClinicalTrials
Waldenstrom Macroglobulinemia 1 D008258 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 728917-18-8
ChEMBL CHEMBL1743088
FDA SRS BPD4DGQ314
Guide to Pharmacology 8268